Post-Traumatic Stress Disorder Treatment Market is expected to grow with a 5% CAGR during 2023 to 2033

The rising incidence of PTSD due to traumatic events such as natural disasters, terrorist attacks, and armed conflicts is a major driver of the PTSD treatment market.

According to Future Market Insights, the Post-Traumatic Stress Disorder (PTSD) Treatment Market sales would expand at a 5% CAGR between 2023 and 2033. The global Post-Traumatic Stress Disorder (PTSD) Treatment market is anticipated to reach US$ 27.37 billion by 2033. The rising prevalence of PTSD globally may be ascribed to the market's rise.

According to the National Centre for PTSD, 7-8% of the US population will develop PTSD at some point in their lives, with higher numbers among military veterans and those who have experienced sexual assault or other types of trauma. The COVID-19 pandemic has also been identified as a potential cause of PTSD, with healthcare personnel, first responders, and persons directly affected by the virus being particularly vulnerable.

Get a Sample Copy of the Report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-16801

Furthermore, there is a rising emphasis on the use of digital therapies and other non-pharmacological treatments to treat PTSD. Virtual reality exposure treatment (VRET), for example, has shown promise in lowering PTSD symptoms by allowing clients to face their experience in a safe and controlled environment. Limbix and Psious, for example, are creating VRET platforms for the treatment of PTSD and other mental health issues.

Key Takeaways from the Market Study

• From 2023 to 2033, the market for Post-Traumatic Stress Disorder (PTSD) Treatment is expected to grow at a 5% CAGR.
• In 2023, antidepressants are expected to account for 41% of the market for Post-Traumatic Stress Disorder (PTSD) treatment.
• North America is expected to have 43% of the market for Post-Traumatic Stress Disorder (PTSD) Treatment in 2023.
• The Post-Traumatic Stress Disorder (PTSD) Treatment market in Europe is expected to account for 42% of the total by 2023.

“As the prevalence of PTSD continues to rise, the need for effective and accessible treatments will only become more pressing. While there is still much work to be done, the growing focus on PTSD treatment is a positive step forward in improving the lives of individuals affected by this debilitating condition,” states an FMI analyst.

Contact Our Market Research Specialist@ https://www.futuremarketinsights.com/ask-question/rep-gb-16801

Competitive Landscape

Key players in the Post-Traumatic Stress Disorder (PTSD) Treatment market are: Jazz Pharmaceuticals, Aptinyx, Otsuka Pharmaceutical Development & Commercialization, Inc., Bionomics Limited, Merck KGaA, Pfizer Inc., Aurobindo Pharma Limited, GlaxoSmithKline plc, Viatris Inc., Jubilant Pharmova

• Otsuka has also partnered with the US Department of Veterans Affairs (VA) to conduct a clinical trial of a medication called samidorphan (ALKS 5461) for the treatment of PTSD. Samidorphan is an opioid system modulator that is being investigated for its ability to reduce symptoms of PTSD, including anxiety, depression, and hyperarousal.
• Bionomics Limited is a biopharmaceutical company that has developed a medication called BNC210, which is being investigated as a potential treatment for PTSD (Post-Traumatic Stress Disorder). BNC210 is a small molecule drug that acts as a negative allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR), which is thought to play a role in the development and maintenance of PTSD symptoms.

Key Segments Profiled in the Post-Traumatic Stress Disorder (PTSD) Treatment Industry Survey

By Drug Class:

• Antidepressants
• Anti-anxiety Drugs
• Antipsychotics
• Other Drug Classes

By Distribution Channel:

• Retail Pharmacies
• Online Pharmacies

Contact Sales for Further Assistance in Purchasing this Report@ https://www.futuremarketinsights.com/checkout/16801